Effect of 3,4-diaminopyridine on the time course of decay of compound muscle action potential augmentation in the Lambert-Eaton myasthenic syndrome

Muscle and Nerve

Volumn 21, Issue 9, 1998, Pages 1196-1198

  Maddison, Paul ^a   Newsom Davis, John ^a   Mills, Kerry R ^a  

^a RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

3,4 diaminopyridine; Augmentation; Calcium ions; Lambert Eaton myasthenic syndrome

Indexed keywords

3,4 DIAMINOPYRIDINE; AZATHIOPRINE; PREDNISOLONE;

ADULT; AGED; ARTICLE; CALCIUM TRANSPORT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG INDICATION; EATON LAMBERT SYNDROME; FEMALE; HUMAN; MALE; MUSCLE ACTION POTENTIAL; MUSCLE STRENGTH; PRESYNAPTIC NERVE; PRIORITY JOURNAL; SODIUM CALCIUM EXCHANGE;

4-AMINOPYRIDINE; ACTION POTENTIALS; ADULT; AGED; FEMALE; FINGERS; HUMANS; LAMBERT-EATON MYASTHENIC SYNDROME; MALE; MIDDLE AGED; MUSCLE CONTRACTION; MUSCLE, SKELETAL; REACTION TIME;

EID: 0031881055     PISSN: 0148639X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4598(199809)21:9<1196::AID-MUS11>3.0.CO;2-Q     Document Type: Article

References (15)

1. 2+ efflux mechanisms following depolarization evoked calcium transients in cultured rat sensory neurones. J Physiol 1992;455:567-583.
2. 2-adrenoceptors: insights into the role of N-and L-type calcium channels. Brain Res 1996;721:101-110.
3. Kirsch GE, Narahashi T: 3,4-Diaminopyridine. A potent new potassium channel blocker. Biophys J 1978;22:507-512.
4. Lambert EH, Elmqvist D: Quantal components of end-plate potentials in the myasthenic syndrome. Ann NY Acad Sci 1971; 183:183-199.
5. Lundh H, Thesleff S: The mode of action of 4-aminopyridine and guanidine on transmitter release from motor nerve terminals. Eur J Pharmacol 1977;42:411-412.
6. Lundh H, Nilsson O, Rosén I: Treatment of Lambert-Eaton syndrome: 3,4-diaminopyridine and pyridostigmine. Neurology 1984;34:1324-1330.
7. Luther PW, Yip RK, Bloch RJ, Ambesi A, Lindenmayer GE, Blaustein MP: Presynaptic localization of sodium/calcium exchangers in neuromuscular preparations. J Neurosci 1992;12: 4898-4904.
8. Maddison P, Newsom-Davis J, Mills KR: Effect of cooling on the time course of decay of post-activation augmentation of muscle responses in the Lambert-Eaton myasthenic syndrome. Neurology (in press).
9. McEvoy KM, Windebank AJ, Daube JR, Low PA: 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med 1989;321:1567-1571.
10. 2+ homeostasis. Prog Neurobiol 1991;37:255-285.
11. Molgó J, Lundh H, Thesleff S: Potency of 3,4-diaminopyridine and 4-aminopyridine on mammalian neuromuscular transmission and the effect of pH changes. Eur J Pharmacol 1980; 61:25-34.
12. Motomura M, Johnston I, Lang B, Vincent A, Newsom-Davis: An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 1995;58:85-87.
13. Newsom-Davis J, Murray NMF: Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome. Neurology 1984;34:480-485.
14. Thomsen RH, Wilson DF: Effects of 4-aminopyridine and 3,4-diaminopyridine on transmitter release at the neuromuscular junction. J Pharmacol Exp Ther 1983;227:260-265.
15. Werth JL, Usachev YM, Thayer SA: Modulation of calcium efflux from cultured rat dorsal root ganglion neurons. J Neurosci 1996;16:1008-1015.